Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
an educational grant from
Merck Sharp & Dohme Corp.
Head and neck squamous cell carcinoma (HNSCC) represent a
heterogeneous group of tumors that originate in the oral cavity,
nasal cavity, paranasal sinuses, hypopharynx, oropharynx,
nasopharynx, and larynx. It’s estimated that 48,000 new cases are
diagnosed annually in the US, with a median age of onset at 60, and
is more common in men than women. Historically HNSCC has been
associated with tobacco and alcohol use, however, during the past
decade, infection with HPV has been implicated in the pathogenesis
of a growing subset of HNSCCs. Despite advances and innovations in
past years, the prognosis for metastatic disease remains poor.
Fortunately, novel immunotherapies have recently become available
and have shown improved efficacy, tolerability, and safety.
Sequencing treatment depends on several factors, to include the
stage of the disease, previous treatment, biomarkers, and patient
co-morbidities. Combination therapy has also shown promising results
however healthcare providers need to realize the implications of
managing adverse events and patient adherence to prolong progression
free and overall survival, as well as improve patient quality of
Upon completion of this
activity, participants will be able to:
Assess recent clinical data on
immunotherapies in the first-line treatment of metastatic head
and neck squamous cell carcinoma (HNSCC)
Examine single-agent and
immune-based combination regimens for the management of patients
with recurrent/metastatic head and neck cancer, including as
upfront treatment or after progression on platinum chemotherapy
Identify metastatic HNSCC patients
who would potentially benefit from the use of checkpoint
Analyze strategies to optimally
sequence immunotherapy regimens in metastatic HNSCC
Explore strategies to mitigate
immune-related adverse events in patients with HNSCC receiving
immunotherapy or multimodal combinations with immunotherapy
||Gary Owens, MD
Gary Owens Associates
serves on as a consultant for Lilly, ICON, Magnolia
Innovation, MCRA, Octave Biosciences, Vertex and Xcenda.
His presentation has been peer reviewed for any bias.
MD has no financial relationships with ineligible
companies to disclose.
Jeremy Williams has no financial relationships with
ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial
relationships with ineligible companies to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by an educational grant from
Merck Sharp & Dohme Corp.
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue